

Naloxone and Overdose Front Line Workers Pack



This manual provides the educator with the core knowledge that must be transmitted to the participant.

**This manual is only to be used by a staff member that has received Naloxone and Overdose Awareness Training by recognised Trained Trainers.**

**The manual should be used in conjunction with the Videos 1 – 5 on [www.drugs.ie/naloxone](http://www.drugs.ie/naloxone) which all the participants must view**

The manual has been designed to assist the trainer in delivering Overdose and Naloxone training to all service users. This manual contains also contains forms:

Form	Description	Completed by worker	Completed by GP
F.1	To be completed <b><u>when ALL overdose training is provided</u></b> and then if appropriate given to the prescribing GP	X	
F.3	Naloxone Project Data Recording: Use and Supply		X
F.4	Naloxone Project Supply Consent to Share Information for Evaluation Purposes	X	X
F.5	Incident Follow Up Report – <b><u>To be completed when the Prenoxad product is administered</u></b>	X	X

**Front line workers one to one Overdose Awareness and Naloxone Training**

We do advise that Service users / Clients view the videos before or during the training that are on <http://www.drugs.ie/resources/naloxone/> these videos can be downloaded onto a computer or to a smart phone.

**Training has to cover:**

- ✓ overdose risks: polydrug (especially benzodiazepines) and alcohol use, getting older, post-detox/rehab/prison
- ✓ what naloxone can and can't do: it just reverses opioid overdose.
- ✓ Where to keep naloxone
- ✓ If someone has also taken too many other drugs or too much alcohol, it won't reverse their effects
- ✓ how to identify an opioid overdose – lack of consciousness, shallow or no breathing, 'snoring', and blueing of the lips and fingertips
- ✓ Calling an Ambulance Acknowledge that there may be fears about calling 112
- ✓ Advise on procedures to obtain resupplies of used, lost or expired naloxone

**Steps to take in responding to an overdose\***

- ✓ If breathing place into recovery position, dial 112, naloxone
- ✓ If not breathing call 112/ and or direct someone to, AED/chest compressions, Naloxone, breathing, recovery and continue
- ✓ CPR
- ✓ Recovery position
- ✓ Calling an Ambulance
- ✓ How to use naloxone, including addressing any fears about needles and injecting
- ✓ How to get naloxone replaced when it has either been used or is approaching its expiry date


**What is an opioid overdose**

Due to their effect on the part of the brain which regulates breathing, opioids in high doses can cause respiratory depression and death.

In cases of fatal overdose, the victim's breathing slows to the point where oxygen levels in the blood fall below the level needed to transfer oxygen to the vital organs. Typically, the individual becomes unresponsive, blood pressure progressively decreases and the heart rate slows, ultimately leading to cardiac arrest. Death can occur within minutes of opioid ingestion. But often, prior to death there is a longer period of unresponsiveness lasting up to several hours. This period is sometimes associated with loud snoring, leading to the term "unroutable snorers".

**An opioid overdose** can be identified by: ( See Video 1 )

- ✓ Heavy intoxication, lethargy etc.
- ✓ Pale skin, lips/fingernails 'bluish' tinge
- ✓ Pinpoint pupils (not with everyone)



### **Observable opioid overdose signs**

- ✓ No response to noise or touch – 'unroutable'
- ✓ Loss of consciousness
- ✓ Breathing problems e.g. slow/shallow breathing, heavy snoring/rasping breaths or not breathing at all

The time between a person actually using the drug(s) and slipping into an overdose varies from a few minutes to several hours, this is dependent on what drugs they have taken and how much they have used.

### **Overdose Risk factors**

- ✓ Injecting rather than smoking drugs
- ✓ Polydrug use, particularly when mixing depressant drugs such as heroin, methadone, alcohol, and benzodiazepines
- ✓ Variable quality of street drugs.
- ✓ Using in unfamiliar surroundings
- ✓ Using with unfamiliar people
- ✓ Having a recent history of non-fatal overdose
- ✓ Underlying mental health problems (such as depression / low mood)
- ✓ Not being in a drug treatment programme
- ✓ Loss/reduction of tolerance following detox / rehab or a prison sentence.
- ✓ The risks of overdose are increased during the first two weeks of leaving prison.
- ✓ Beginning / ending opioid substitution medication prescribing.
- ✓ Difficult life events, such as bereavement, loss of contact with children, separation / divorce.

### **What is Naloxone ? ( see video 4 )**

Naloxone is an antidote that rapidly, but temporarily, reverses the effects of heroin and other opioids. Among the effects of heroin that can be reversed is suppressed breathing – meaning naloxone has the potential to save lives.

Naloxone is short acting and the effects of Naloxone can last about 20 minutes depending on what opioids the individual has used.

Therefore Naloxone only temporarily reverses the effects of overdose and therefore there is a risk that the person can return back into an overdose especially if the duration of the opioid is long acting for example Methadone.


**Not a substitute for calling 112** but keeps people alive until the emergency services arrive.

**Has no effect** on other drugs used like alcohol, benzos etc.

Naloxone itself has no psychoactive properties and “no intoxicating effects or misuse potential”.

**Having identified an overdose: ( See Video 3)**


**Intramuscular**



1. Call an ambulance
2. Give rescue breaths and or Chest Compressions if the person is not breathing
3. Put them in the recovery position if they are breathing
4. Inject the initial recommended one dose amount of naloxone (400mcg), wait (2-3 minutes per SmPC). If unresponsive, inject another single dose amount. Repeat as necessary
5. Stay with the person until the ambulance arrives

**Having identified an overdose: ( See Video 5)**

**Intranasal**




**Each container contains one dose of 1.8mg naloxone .**

- 1. Call an ambulance**
- 2. Give rescue breaths and or Chest Compressions if the person is not breathing**
- 3. Put them in the recovery position if they are breathing**
- 4. Lay them on their back. Support the back of the neck, let head tilt back. Clear away anything you see blocking their nose.**
- 5. Gently insert spray nozzle into one nostril. Press firmly on the plunger until it clicks and gives the dose. Remove the nozzle from the nostril.  
*If possible, note which nostril you used.***
- 6. If after 2 minutes the person is still unresponsive administer another dose of Naloxone**
- 7. Stay with the person until the ambulance arrives**

**Once the training has taken please complete the Training Checklist F.1 this has to be completed**




[http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC\\_PA1176-003-001\\_20102016123104.pdf](http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1176-003-001_20102016123104.pdf)




## Administration of Naloxone (see Video 4)

### Injecting Prenoxad Injection


How to open, assemble and inject Prenoxad Injection (naloxone hydrochloride 1mg/1ml solution for injection)




Remove the clear film wrapping by pulling the tear strip on the side of the box. Twist the outer plastic to break the tamper evident seals and open




The box contains 1 syringe of Prenoxad Injection and two 23 gauge 1 ¼ inch needles for intramuscular injection




Unscrew the clear plastic top from the syringe




Peel back the backing paper from the needle packet and remove the needle, keeping it in its protective sheath




With the needle still in its sheath, screw the blue fitting onto the syringe



Gently twist the needle sheath and remove it from the syringe. Twisting the needle sheath instead of pulling it avoids needle stick injury



Hold the syringe like a pen or dart



- Insert the needle at right angles (90 degrees) into the casualty's outer thigh or upper arm muscle, through clothing if necessary
- Rotate the barrel so that the black dosage line can be seen
- Inject the first dose of 0.4 ml Prenoxad Injection by holding the syringe steady and pushing the plunger to the first black line
- Take out the syringe with the needle attached and safely put it back into the case
- Do not re-sheath the needle
- If you need to give another dose, insert the syringe again and inject to the next black line
- After using Prenoxad Injection, keep the syringe in the box and hand it to the ambulance crew so that they know it has been administered

See video 5



Open the container.  
Remove the nasal spray and  
place it within easy reach.



Lay them on their back.  
Support the back of the neck, let head tilt back.  
Clear away anything you  
see blocking their nose.



Hold the spray as shown —  
first two fingers either side  
of the nozzle, thumb ready  
to push the plunger.  
**Don't press to prime or test  
before use.**



Gently insert spray nozzle  
into one nostril. Press firmly  
on the plunger until it clicks  
and gives the dose. Remove  
the nozzle from the nostril.  
If possible, note which nostril you used.

## F.1 Checklist

Name ( Initials)	DOB	Address	GP Name & Address
------------------	-----	---------	-------------------

The person must demonstrate an understanding of the following:

	Trainer Initials
<b>The most common drugs identified in a drug-related death</b> (heroin, methadone, diazepam & alcohol – all CNS depressant drugs) <b>and the physical effects these drugs have</b> (slow, shallow, irregular breathing, slow heart rate, feeling less alert, unconsciousness, not feeling pain)	
<b>The main causes of drug overdose</b> (low tolerance, polydrug use, using too much, using alone, injecting drug use, purity levels)	
<b>High risk times</b> (release from prison, leaving rehab or hospital, recent detox, recent relapse, poor physical or mental health, recent life events, cash windfall, longer-term user, festive periods, weekends or holidays)	
<b>The signs &amp; symptoms of suspected opioid overdose</b> (pinpoint pupils, breathing problems, skin/lip colour, no response to noise or touch, loss of consciousness)	
<b>The common myths</b> (don't inflict pain, give other drugs e.g. stimulants, put in bath/shower, walk person around, leave person on own)	
<b>Knows when to call 112</b> (when person won't wake with shout/shake, status of person and location)	
<b>Knows about the recovery position</b> (person on side, airway open)	
<b>Knows about rescue breathing and CPR</b> (30 compressions, 2 breaths – one cycle of BLS)	
<b>Knows when and how to administer ( IM ) naloxone</b> (unconscious but breathing – admin when in recovery position then every 2-3mins, unconscious but NOT breathing – admin after one cycle of BLS then after every three cycles of BLS. Dose – 0.4mls into outer thigh muscle via clothing. Assembly of syringe)	
<b>Knows when and how to administer (INN) naloxone</b> (unconscious but breathing – admin when in recovery position then every 2-3mins, unconscious but NOT breathing – admin after one cycle of BLS then after every three cycles of BLS Administer INN dose applied into the nose, the spray is activated by depressing the plunger, until it clicks	
<b>Knows that naloxone is short acting</b> (the effects of naloxone wear off after 20-30 mins, possible that overdose may return)	
<b>Knows the importance of staying with the person</b> (do not let the person use any other drugs if they gain consciousness)	
<b>Knows the importance of</b> not re using the product once the pack has been opened.	
<b>Has been informed</b> that a new pack of Naloxone can be re supplied if it has been used	

The above trainee has viewed all videos and the demonstrated an understanding and awareness of opioid overdose, the use of naloxone, calling 112, the recovery position and basic life support

Trainer Name & Signature ..... Date .....

### Form F.3- Naloxone Demonstration Project Data Recording: Use and Supply

<b>Please tick where appropriate and clearly write in block letters or use stamp.</b>			
<b>1. Location of supply:</b>	<b>Name and address:</b>		
<b>2. Prescriber/MCRN:</b>			
<b>3. Please circle prescribed product    Prenoxad                          Nyxoid</b>			
<b>3. Risk assessment</b> Yes <input type="checkbox"/> No <input type="checkbox"/>		<b>4. Training provided:</b> Yes <input type="checkbox"/> No <input type="checkbox"/>	
<b>Completed by:</b>		<b>Completed by:</b>	
<b>5. Referral for Naloxone by:</b>			
<b>6. Consent for recording/ sharing data:</b> Yes <input type="checkbox"/> No <input type="checkbox"/>			
<b>7. Naloxone is provided to: <u>Gender:</u></b> Male <input type="checkbox"/> Female <input type="checkbox"/> Not specified <input type="checkbox"/>			
<b>Name of the patient:</b>		<b><u>DATE OF BIRTH:</u></b>	
<b>Address:</b>		Day    Month    Year	
		□□/ □□/ □□	
<b>8a. Date of Issue:</b> ___/___/___		<b>8b. Supply</b>	
		<ul style="list-style-type: none"> <li>▪ First Supply <input type="checkbox"/></li> <li>▪ Repeat Supply <input type="checkbox"/></li> <li>▪ Spare Supply <input type="checkbox"/></li> <li>▪ Not Known <input type="checkbox"/></li> <li>▪ Refusal by patient <input type="checkbox"/></li> </ul>	
<b>9. Details of the product:</b>		<b>BN:</b>	<b>Expiry:</b> ___/___
			<b>Unique identifier:</b>
<b>10. Last Naloxone supply:</b>		<b>11. Prison release Date:</b>	
Used on Self	<input type="checkbox"/>		
Used on Other	<input type="checkbox"/>		
Lost Kit	<input type="checkbox"/>	___/___/___	
Confiscated	<input type="checkbox"/>		
Expired	<input type="checkbox"/>		
Damaged Kit	<input type="checkbox"/>	<b>12. Court Release Date:</b>	
Refusal by patient	<input type="checkbox"/>	___/___/___	
Not Applicable – First Supply	<input type="checkbox"/>		
Not Known	<input type="checkbox"/>		

## Dataset Items

Detailed below are the dataset items that comprise the agreed dataset for the Naloxone Demonstration Project monitoring. Questions one to six apply to all instances of a kit being supplied (community supply or prison supply). Question six asks if consent has been given to the sharing of the individual's personal data. If yes, then questions seven to 10 should be completed. **If No and consent is not received** the data is still required by the HSE for evaluation and monitoring purposes , **the data will be anatomised**

Questions 11 and 12 apply only to the supply of kits by prisons.

Data item	Notes
<b>1. Location of Supply name and address</b>	This is the location of the service provider. <b>Recording Guidance:</b> Mary Egan will agree with you what should be entered in this field to ensure that your service activity is being identified. <b>Purpose:</b> This data item will be used to monitor returns for each service participating in the Naloxone Project.
<b>2. Prescriber</b>	Name of the prescriber and MCRN, completed in block capital or may use a stamp <b>Purpose:</b> This data item will be used to monitor prescribing rates of those participating in the Naloxone Project
<b>3. Risk assessment</b>	Risk assessment tool as reproduced from the <a href="http://orion-euproject.com/">http://orion-euproject.com/</a> project. See the proposed assessment Appendix 1. The individual who completes the risk assessment clearly write and give role <b>Purpose:</b> This data item will be used to inform regarding the appropriate individuals that require Naloxone.
<b>4. Training</b>	This is the training advice provided by workers to patients prior to prescribing and supply of Naloxone to ensure that the client is informed how to use the product. The worker who completes the risk assessment clearly writes and gives role within the organisation. <b>Purpose:</b> This data item will be used to inform the Prescribing GP regarding the training of individuals that require Naloxone
<b>5. Referral</b>	This is to record who is referring patient for Naloxone and date of referral <b>Purpose:</b> This data is used to see from where patients are being referred from
<b>6. Consent to Data Recording</b>	A Yes/No field indicating whether consent to share their personal data has been given. <b>Recording Guidance:</b> If yes, continue to record all data items. The personal information provided will <b>only</b> be used for the purpose of monitoring and evaluating the use and supply of naloxone and for no other purposes. A person can decide to say No at a further stage in the study, e.g. at the next request and the revised consent form should be filed.. Personal data will only seen by the Project Lead, Mary Egan. All information used in reports will be anonymous. <b>If No</b> and consent is not received <b>the data is still required by the HSE</b> for evaluation and monitoring purposes , <b>the data will be anatomised</b> and will be sent for central analysis and this will not affect your access to Naloxone.

	<p>We would ask that you encourage the person to consent to the recording of the personal information as the data will be invaluable in monitoring how many repeat supplies an individual receives throughout the duration of the Naloxone Project. A hard copy of the written consent should be placed in the medical record.</p>
<p><b>7. Naloxone is provided to:</b></p>	<p>This records whether the kit is provided to the person at risk. Person at risk demographics</p> <ul style="list-style-type: none"> <li>• Gender</li> <li>• Name</li> <li>• Month and year of birth recorded This date should be entered in the format MM/YYYY.</li> <li>• Address: please confirm if NFA: Hostel, rough sleeper, temporary accommodation</li> </ul> <p><b>Recording Guidance:</b> Please indicate precisely who the kit is provided to.</p> <p><b>Purpose:</b> This data item will be used to monitor the ‘reach’ of THN distribution (how many individuals ‘at risk’ have access to a kit) and the total numbers of individuals receiving THN in addition to those persons ‘at risk’. This data item will be used to assess geographic coverage of THN as well as determine areas with increasing use.</p> <p><b>Please note this is from the person’s perspective.</b></p>
<p><b>8a. Date of Issue</b></p>	<p>This is the date on which the kit was issued and should be entered in the format DD/MM/YYYY.</p> <p><b>Purpose:</b> This data item will be used to monitor the distribution of kits throughout the year. The dates of issue, together with other data items will also be used to quality assure the data. E.g. Date of issue, name and date of birth will help identify possible duplicate entries.</p>
<p><b>8b. Supply</b></p>	<p>This records whether the kit is the person’s first supply or if they have previously been provided with a supply of naloxone. The list gives the options:-</p> <ul style="list-style-type: none"> <li>• First Supply</li> <li>• Repeat Supply</li> <li>• Spare Supply</li> <li>• Not Known</li> </ul> <p><b>Recording Guidance:</b> If using Spare Supply to record the issue of a ‘second kit’, the other supply given should be recorded as normal i.e. First Supply or Repeat Supply etc. Please ensure each initial <b>new spare</b> supplied is recorded as a ‘Spare Supply’ and not a ‘Repeat Supply’ ‘Repeat supply’ should be recorded where a previous kit needs to be replaced (i.e. ‘Used on Self’, ‘Used on Other’, ‘Lost Kit’, ‘Confiscated’, ‘Expired’ or ‘Damaged Kit’ ). Similarly, If a spare kit has been used as indicated in Q5, then the <b>replacement supply</b> should be recorded as a ‘repeat supply’.</p> <p><b>Purpose:</b> This data item will be used to monitor the ‘reach’ of THN distribution (how many first supplies made to individuals ‘at risk’), the total numbers of individuals receiving THN in addition to those persons ‘at risk’ (inc. spare supplies) and the frequency of THN re-supply due to use, damage etc. <b>Please note this is from the person’s perspective.</b></p>
<p><b>9. Naloxone details:</b></p>	<p>This is batch number of the product and the expiry date. There also may be a unique identifier on the product which will need to be recorded.</p> <p><b>Recording Guidance:</b> The naloxone lead will agree with you what should be entered in unique identifier field to</p>

	<p>ensure that the product is being identified.</p> <p><b>Purpose:</b> This data item will be used to monitor the route and use of the Naloxone throughout the Naloxone Project</p>
<b>10. Last naloxone supply:</b>	<p>This records what happened to the last supply that was provided. The drop down list contains the options:-</p> <ul style="list-style-type: none"> <li>• Used on Self</li> <li>• Used on Other</li> <li>• Lost Kit</li> <li>• Confiscated</li> <li>• Expired</li> <li>• Damaged Kit</li> <li>• Not Applicable – First Supply</li> <li>• Not Applicable – Spare Supply</li> <li>• Not Known</li> </ul> <p><b>Recording Guidance:</b> If you have recorded in Q4 that this is a ‘repeat supply’ or a ‘spare supply’ to the person, you should record what the previous supply was used for. If this is the person’s first supply please select ‘Not applicable – First Supply’ from the drop down box. If this is the person’s first spare (no previous spare received) please select ‘Not applicable – Spare Supply’..</p> <p><b>Purpose:</b> This data item will assist in evidencing reasons for re-supply (e.g. how many kits were used on those at risk of opioid overdose).</p> <p><b>Please note this is from the person’s perspective.</b></p>
<b>11. Prison Release Date (if applicable)</b>	<p>This is the date the person at risk is due for release from prison and should be entered in the format DD/MM/YYYY.</p> <p><b>Recording Guidance</b> If known, the prisoner’s ‘Earliest Date of Release’ should be recorded.</p> <p><b>Purpose:</b> This will assist in evidencing the impact of THN on prisoners who are vulnerable to overdose within 4 weeks following release not on a OST programme. <i>It is recognised that the four week period following prison release is a crucial period for former prisoners with regard to risk of death from overdose.</i></p>
<b>12. Court Date</b>	<p>The date of court appearance if release date is not known.</p> <p><b>Purpose:</b> In the absence of a release date, court date will assist in evidencing the impact of THN on prisoners who are vulnerable to overdose within 4 weeks following release.</p>



## F.4- Naloxone Project Supply Consent to Share Information for Monitoring Purposes

### Naloxone Demonstration Project Supply

#### Consent to Share Information for Evaluation Purposes.

In order to monitor the provision of Naloxone, the prescribing doctor has been requested to send the following information to Tim Bingham, Lead Trainer of the project. This information provides data to ensure the availability of Naloxone is maintained and continued.

Your information which will be sent will be:

- Your name, and date of birth ( **If consent is not provided Gender and DOB**)
- That Naloxone has been supplied to you
- The Date on which it was supplied
- Whether you had received a previous supply
- How you used the previous supply
- Details of the batch number of the Naloxone supplied to you
- Kept only for as long as needed and disposed by a certified confidential waste disposal system
- Stored safely

The personal information provided will **only** be used for the purpose of monitoring the use and supply of naloxone and for no other purposes.

When this information is used to provide an evaluation or report, your information will be anonymous and your name and date of birth will not appear in any report sent to any other person. Your confidentiality is assured except when there is an issue around; child safety; violence to yourself or others; the courts request information

I agree to Dr \_\_\_\_\_ MCRN \_\_\_\_\_ releasing the information about Naloxone prescribed to me as described above to Mary Egan for the purpose of monitoring the Naloxone project.

**If consent is not received some data is still required by the HSE for evaluation and monitoring purposes**, the data will be anatomised and will be sent for central analysis and this will not affect your access to Naloxone.

A hard copy of the F4 form should be placed in the medical record.

Patient \_\_\_\_\_ Name \_\_\_\_\_ (Printed)

Signature \_\_\_\_\_ Date \_\_\_\_\_

Also you can change your mind at any time by contacting the doctor. This will be recorded on your file and logged onto this original consent form.

Patient Name: \_\_\_\_\_ Date consent withdrawn \_\_\_\_\_

Signature of Doctor: \_\_\_\_\_ MCRN \_\_\_\_\_

## **F.5 Incident Follow Up Report**

***The new F5 form in Excel spreadsheet should be used when Naloxone has been administered. This form is used to track incidences and any reported incident management issues.***

### **Contact details for the Naloxone Project**

**Jim Kee**

[james.kee@hse.ie](mailto:james.kee@hse.ie)

**Tim Bingham**

National Lead Trainer

Tel 0864104098

Email [tim.bingham@hse.ie](mailto:tim.bingham@hse.ie)